Speaker illustration

Professor Peter John Meikle

Baker Heart and Diabetes Institute, Melbourne (Australia)

Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention

Event: ESC Congress 2018

Topic: Lipid-Lowering Agents

Session: Cardiovascular risk and its modification

Thumbnail